EMA Authorised: Sunlenca (lenacapavir sodium) — Gilead Sciences Ireland Unlimited Company

View source ↗

Summary

EMA authorised Sunlenca (lenacapavir) for HIV infections, granting EU marketing authorisation to Gilead Sciences Ireland Unlimited Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• SUNLENCA (LENACAPAVIR SODIUM)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Gilead Sciences Ireland Unlimited Company. Decision date: 19/02/2026